Biotech Values

[ciotera]

Re: CGRP/migraine market has become crowded

Actually, there is only one that's competing with it directly within the acute space, Ubrelvy from Allergan (soon to be Abbvie). And it also launched very recently. But Nurtec is also going to get an indication in preventive soon, so then it'll compete against the injectables (and the most recently approved IV Vyepti). Allergan (AbbVie) will get approval for atogepant in preventive soon. So, they will have urogepant for acute and atogepant (and Botox) for preventive. But NURTEC will be the only oral CGRP that's both for acute and prevention.